<DOC>
	<DOCNO>NCT02610153</DOCNO>
	<brief_summary>This prospective observational study assess predictive factor poor control international normalize ratio ( INR ) determine treatment strategy receive patient poor control INR real-life clinical practice explore effectiveness safety strategy patient non-valvular atrial fibrillation start vitamin K antagonist ( VKA ) treatment</brief_summary>
	<brief_title>Subtherapeutic INR Levels Patients With AVK : Incidence , Associated Factors , Prognosis Control Strategies</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<criteria>Patients age â‰¥ 18 year . Patients diagnosis nonvalvular atrial fibrillation accord criterion Spanish Agency Medicines Medical Devices ( AEMPS ) ( 2013 ) treat cardiology practice . Patients start treatment vitamin K antagonist first two month treatment . Patients access least 80 % INR test perform treatment vitamin K antagonist expect available . Patients mental physical capacity complete study questionnaire give inform consent participate study . Patients mitral stenosis another significant valve disease specific treatment schedule already perform ( prosthesis valvuloplasty ) . Patients hospitalise time inclusion study . Patients life expectancy le 13 month . Patients participate clinical trial . Patients receive double antiplatelet therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>